A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction

NCT06161246 | Completed Phase 4

• 1 other identifier: GLI.04.US.SL.028
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label, single-center, randomized, split-face, controlled study to assess the effect of comfort intervention on pain during treatment injection compared against non-comfort intervention.

Conditions

Injection Site Discomfort

Outcome Measures

Primary Outcomes (1)

• Visual Analogue Scale

  Visual Analogue Scale is a 11-point psychometric scale that specifies the level of pain. Subject will be shown a photo of a VAS and verbally report a pain score between 0 and 10, which will be captured by a clinic staff. A score of 0 corresponds to no pain felt and a score of 10 corresponds to very high pain.

  Baseline

Secondary Outcomes (1)

• Self-assessment questionnaire

  Baseline

Study Arms (1)

Treatment Group

EXPERIMENTAL

Subjects will be treated for correction of glabellar lines with Dysport and comfort intervention on one side and Dysport only on the other side depending on pre-determined randomization. Subjects will complete the study assessments and end the study.

Device: Vibrating Beauty Bar

Interventions

Vibrating Beauty Bar DEVICE

A vibrating beauty bar will be used at the injection site for patient comfort.

Also known as: Vibration therapy

Treatment Group

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Adult subjects aged 18-65 years
• Females or males
• Having any Fitzpatrick skin types I-VI
• Any races and ethnicities
• Having any self-assessed pain tolerance, with a minimum of 5 subjects in each category (low, medium, and high pain tolerance)
• Subject with intent to undergo correction of the glabellar lines (frown lines between the eyebrows)
• Subject with moderate-to-severe glabellar lines as assessed by investigator using Glabellar Line Severity Scale (GLSS).
• Subject with no history of aesthetic injection, i.e., botulinum toxin, collagen, hyaluronic acid, calcium hydroxyapatite, poly L-lactic acid or permanent materials.
• Subject with healthy immune systems
• Subject willing to abstain from any other facial plastic surgical or cosmetic procedure(s) during the duration of the study.
• For female subjects of childbearing potential, she must not be pregnant, breastfeeding or planning pregnancy during the course of the study. Subjects must be willing to take a urine pregnancy test (UPT) prior to all treatment injections.
• Ability of giving consent for participation in the study
• Agreement to adhere to the procedures and requirements of the study and to report to the site on the day(s) and at the time(s) scheduled for the assessments

You may not qualify if:

• Pregnant, breastfeeding, or planning pregnancy during the course of the study, confirmed by UPT.
• Current smokers or consumer nicotine (e.g., cigarettes, e-cigarettes, vaping device with pre-filled pods, vapor tank or mod, chewing tobacco)
• History of allergy or hypersensitivity to botulinum toxin type A, human albumin, lactose, or cow's milk protein
• Subject with signs and symptoms of eyelid or brow ptosis, inability to substantially lessen glabellar lines by physically spreading them apart, or history or presence of facial nerve palsy, as judged by the Investigator.
• Previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions.
• Previous aesthetic treatment in the face with any of the following injection prior to the baseline visit:
• Botulinum toxin
• Collagen, hyaluronic acid
• Calcium hydroxylapatite, poly L-lactic acid, fat or permanent materials (non-biodegradable)
• Previous treatment/procedure in the face in the previous 2-4 weeks that, in the Investigator's opinion, would interfere with the study injections and/or study assessments or exposed the study subject to undue risk by study participation, or planning to undergo any of these procedures affecting the treatment area at any time during the study e.g.,
• Resurfacing (laser, photo modulation, light, radiofrequency, ultrasound, chemical peel, dermabrasion, or other ablative/non-ablative procedures)
• Needling or mesotherapy
• Cryotherapy
• Presence of any disease or lesions near or on the glabellar region, e.g.,
• Inflammation, active, or chronic infection in or near the treatment area

Sponsors & Collaborators

• Galderma R&D: lead
• DeNova Research: collaborator

Study Sites (1)

DeNova Research

Chicago, Illinois, 60611, United States

Location

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Subjects will receive comfort intervention on one side of face, and will not receive comfort intervention on the other side of face.

Study Record Dates

• First Submitted: November 30, 2023
• First Posted: December 7, 2023
• Study Start: October 23, 2023
• Primary Completion: February 15, 2024
• Study Completion: February 15, 2024
• Last Updated: March 22, 2024

Record last verified: 2023-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)